Meanwhile, in R/R CLL, the most common leukemia in adults, the reported CR rates of anti-CD19 CAR-T cell therapy range from 18 to 29%, which are lower than in other B-cell malignancies [2, 5, 7, 10–13, 15, 16]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.